Evidence map›Paper›PMID 38707652›Full record

ArticleJCEM case reports2024

The Role of Imatinib in Pediatric Type 1 Diabetes.

Kristen Lavelle, Chester Chamberlain, Michael German, Mark Anderson, Angel Nip, Stephen E Gitelman

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JCEM case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Are We Ready With Prevention for Type 1 Diabetes?Diabetes/metabolism research and reviews · 2025
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kristen LavelleDepartment of Medicine, Division of Endocrinology and Metabolism, University of California, San Francisco, CA 94143, USA.ORCID https://orcid.org/0000-0002-7049-1701
Chester ChamberlainEli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California, San Francisco, CA 94143, USA.
Michael GermanDepartment of Medicine, Division of Endocrinology and Metabolism, University of California, San Francisco, CA 94143, USA.
Mark AndersonDepartment of Medicine, Division of Endocrinology and Metabolism, University of California, San Francisco, CA 94143, USA.
Angel NipDepartment of Pediatrics, Division of Endocrinology, University of California, San Francisco, CA 94143, USA.
Stephen E GitelmanDiabetes Center, University of California, San Francisco, CA 94143, USA.ORCID https://orcid.org/0000-0003-4186-4107

Funding

DIABETES, ENDOCRINOLOGY &METABOLISM TRAINING PROGRAMT32DK007418 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI EDWARD C HSIAO · 1986 to 2026
$14.3M
NIDDK NIH HHS T32 DK007418
6 · The paper itself

Abstract

We report the first case of imatinib use in an adolescent with diabetes and suggest that it impacts the natural course of disease. A 14-year-old male patient presented in diabetic ketoacidosis (DKA) and was diagnosed with presumed autoantibody-negative type 1 diabetes (T1D) as well as myeloid neoplasm with platelet-derived growth factor receptor beta (PDGFRB) rearrangement. After starting exogenous insulin and imatinib, he experienced a 1.7-point reduction in glycated hemoglobin (HbA1c) and a 71% reduction in insulin requirement with sustained partial diabetes remission. Our case suggests imatinib as a potential therapeutic agent for pediatric T1D.

Indexed as

case reportdiabetesimatinibpediatric

Identifiers

PMID38707652
PMCPMC11066799

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.